Exploring Three Undervalued Small Caps With Insider Action In The Region
In This Article:
As global markets display mixed reactions with a notable pivot towards small-cap and value shares, investors are keenly observing these segments for potential opportunities. In such an environment, identifying undervalued small-cap stocks with significant insider action can offer intriguing prospects for discerning investors looking to capitalize on market shifts and underlying economic signals.
Top 10 Undervalued Small Caps With Insider Buying
| Name | PE | PS | Discount to Fair Value | Value Rating |
|---|---|---|---|---|
| Dundee Precious Metals | 8.8x | 3.0x | 45.84% | ★★★★★★ |
| Hanover Bancorp | 9.0x | 2.0x | 45.60% | ★★★★★☆ |
| Thryv Holdings | NA | 0.7x | 26.07% | ★★★★★☆ |
| CVS Group | 21.6x | 1.2x | 40.01% | ★★★★☆☆ |
| Franklin Financial Services | 9.8x | 2.0x | 31.19% | ★★★★☆☆ |
| PCB Bancorp | 10.5x | 2.8x | 35.07% | ★★★★☆☆ |
| Chatham Lodging Trust | NA | 1.4x | 12.53% | ★★★★☆☆ |
| Russel Metals | 9.4x | 0.5x | -10.77% | ★★★☆☆☆ |
| PowerCell Sweden | NA | 4.5x | 40.55% | ★★★☆☆☆ |
| Community West Bancshares | 18.7x | 2.9x | 42.25% | ★★★☆☆☆ |
Let's take a closer look at a couple of our picks from the screened companies.
Marksans Pharma
Simply Wall St Value Rating: ★★★☆☆☆
Overview: Marksans Pharma is a pharmaceutical company with operations focused on the manufacturing and marketing of formulation products, holding a market capitalization of approximately ?21.77 billion.
Operations: The pharmaceuticals segment generated ?21.77 billion in revenue, with a gross profit margin of 52.32% as of the latest reporting period, reflecting significant operational efficiency in managing costs relative to sales.
PE: 29.6x
Recently, Marksans Pharma showcased a notable financial performance with a year-on-year revenue increase to INR 22.28 billion for FY 2024, up from INR 19.11 billion. Their net income also rose to INR 3.14 billion, reflecting a robust growth trajectory. Insider confidence is evident as they recommended increasing the dividend to INR 0.60 per share, signaling strong future prospects and financial health. This move aligns with their earnings growth forecast of 21.63% annually, underscoring their potential as an undervalued entity in the pharmaceutical sector.
-
Navigate through the intricacies of Marksans Pharma with our comprehensive valuation report here.
-
Gain insights into Marksans Pharma's past trends and performance with our Past report.
Ryman Healthcare
Simply Wall St Value Rating: ★★★☆☆☆
Overview: Ryman Healthcare operates integrated retirement villages for older people, with a market capitalization of approximately NZ$5.72 billion.
Operations: The entity generates NZ$687.56 million from its integrated retirement villages, with a gross profit margin recently reported at 5.19%. Notably, the net income margin has seen fluctuations, currently standing at approximately 0.69%.